MedTrace Logo

Immunophenotyping Profiling in Patients With Primary Nephrotic Syndrome

NCT07702981 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2026-07-14

No results posted yet for this study

Summary

Immunophenotyping profiling of patients with primary MN, primary FSGS and MCD. Evaluation of these immune cell subsets as possible biomarkers to track response to treatment or disease relapse.

Conditions

Interventions

DRUG

Rituximab (MABTHERA® or RITUXAN®).

Patients with primary MN treated with Rituximab

DRUG

Corticosteroids (CS)

Patients with MCD treated with Corticosteroids

DRUG

Corticosteroids (CS)

Patients with primary FSGS treated with Corticosteroids

Sponsors & Collaborators

  • University Hospital, Ioannina

    lead OTHER

Principal Investigators

  • Evangelia Dounousi, Medical Degree · University of Ioannina

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2025-11-01
Completion
2026-02-01

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07702981 on ClinicalTrials.gov